Browse News

Found 20,755 articles

• Switch Therapeutics Expands Leadership Team with Key Appointments

  3/28/2023

  Switch Therapeutics today announced the appointments of Craig Blanchette, Ph.D., as Senior Vice President, Research and Michael Wolfe as Senior Vice President, Finance and Operations, effective immediately.

• 

  ArriVent Snags $155M for NSCLC Treatment in Record Low Series B Period

  3/27/2023

  Despite a tough financing market, ArriVent Biopharma closed a $155 million Series B to fund a pivotal Phase III trial of its non-small cell lung cancer asset.

• Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

  3/27/2023

  GSK plc (LSE/NYSE: GSK) today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab-gxly compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.

• Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)

  3/27/2023

  Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer.

• KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status

  3/27/2023

  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 NRG‑GY018 trial investigating KEYTRUDA.

• Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage TherapeuticsAppointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton

  3/24/2023

  ADvantage Therapeutics, Inc. announced the election of James O’Neill — a recognized leader in health, aging, and longevity — to its Board of Directors.

• BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products

  3/23/2023

  BioStem Technologies is commending the U.S. Department of Health and Human Services Office of Inspector General's (HHS OIG) recent recommendation for the Centers for Medicare and Medicaid Services (CMS) to quickly address issues associated with Average Sales Price (ASP) reporting requirements for skin substitute products.

• Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/23/2023

  Cidara Therapeutics, Inc. today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline.

• Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Analytical Release Tests Completed

  3/23/2023

  Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO) is pleased to announce the successful completion of a full set of analytical tests required to verify the quality of the cells manufactured during three Process Qualification ("PQ") runs of the end-to-end process for HEMO-CAR-T production.

• PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

  3/23/2023

  PureTech Health plc and Royalty Pharma announced that Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million, with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones.

• Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting

  3/23/2023

  Sosei Group Corporation announces the election of Ms. Eiko Tomita to the Board of Directors as an Independent External Director, and the promotion of Ms. Candelle Chong to Executive Vice President and Chief of Staff at the Company’s 33rd Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held in Tokyo.

• Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)

  3/23/2023

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.

• Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/23/2023

  Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022.

• JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

  3/22/2023

  JanOne announced that on March 9, 2023 they entered into a Stock Purchase Agreement with VM7, a Delaware corporation, under which VM7 agreed to acquire all of the outstanding equity interests of ARCA Recycling, Inc, Customer Connexx LLC and ARCA Canada Inc. Virland Johnson, who has served as ARCA Recycling's CFO and COO for several years is the principal of VM7.

• Truveta and Alpine Immune Sciences Announce Strategic Partnership to Access Truveta’s Community to Accelerate Recruitment to Povetacicept Clinical Trials

  3/22/2023

  Today, Truveta and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory diseases.

• ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES

  3/22/2023

  Annovis Bio, Inc. today announced the Company will be making two presentations at the upcoming AD/PD ™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden.

• Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda

  3/22/2023

  Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of Directors, effective April 1, 2023.

• New Model N Study Finds Quality Channel Data Management Drives Performance

  3/21/2023

  Model N, Inc. released a new commissioned study by Forrester Consulting that shows how improved channel data management leads to better trust, collaboration, and bottom-line results.

• Cytovation appoints Iman Barilero as Chief Development Officer

  3/21/2023

  Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.

• Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

  3/20/2023

  Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2022.